Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00004
|
|||||
| Drug Name |
Gaboxadol
|
|||||
| Synonyms |
4,5,6,7-Tetrahydroisoxazole(5,4-c)pyridin-3-ol; 4,5,6,7-Tetrahydroisoxazolo(5,4-c)pyridin-3-ol; 4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-3-one; Gaboxadol (USAN/INN); Gaboxadol [USAN:INN]; Gaboxadolum; Gaboxadolum [Latin]; Isoxazolo(5,4-c)pyridin-3(2H)-one, 4,5,6,7-tetrahydro-, hydrate; LU 2030; LU-2-030; Lu 02-030; Lu-02-030; MK-0928; THIP
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Insomnia [ICD11: 7A0Z] | Discontinued in Phase 3 | [1] | |||
| Therapeutic Class |
Hypnotics and Sedatives
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C6H8N2O2
|
|||||
| Canonical SMILES |
C1CNCC2=C1C(=O)NO2
|
|||||
| InChI |
InChI=1S/C6H8N2O2/c9-6-4-1-2-7-3-5(4)10-8-6/h7H,1-3H2,(H,8,9)
|
|||||
| InChIKey |
ZXRVKCBLGJOCEE-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 64603-91-4
|
|||||
| Pharmaceutical Properties | Molecular Weight | 140.14 | Topological Polar Surface Area | 50.4 | ||
| Heavy Atom Count | 10 | Rotatable Bond Count | 0 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 3 | |||
| XLogP |
-0.9
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103286434
, 104121647
, 11111836
, 11111837
, 11113715
, 11335386
, 11360625
, 11364378
, 11366940
, 11369502
, 11371576
, 11373822
, 11377664
, 11461597
, 11467000
, 11468120
, 11485296
, 11486650
, 11489406
, 11490544
, 11491987
, 11495298
, 12015406
, 14747760
, 15194598
, 26751902
, 29222582
, 47206216
, 47211771
, 47365059
, 47515197
, 47588874
, 47885286
, 47959606
, 47959607
, 48110332
, 48184876
, 48259099
, 49698969
, 49987818
, 50104580
, 50684001
, 5651498
, 5694188
, 57321806
, 586282
, 7980780
, 81065560
, 8152193
, 90341079
|
|||||
| ChEBI ID |
ChEBI:34373
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | PAT1 | Transporter Info | Proton-coupled amino acid transporter 1 | Substrate | [2] | |
| References | ||||||
| 1 | ClinicalTrials.gov (NCT00209937) A Prospective Active-Reference Study of Gaboxadol in Primary Insomnia | |||||
| 2 | Intestinal gaboxadol absorption via PAT1 (SLC36A1): modified absorption in vivo following co-administration of L-tryptophan. Br J Pharmacol. 2009 Aug;157(8):1380-9. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.